Competitors moving in to fill Teva's Cymbalta generic void?
This article was originally published in Scrip
Executive Summary
A clutch of Indian firms could be among those that stand to potentially gain from the general "void" created by Teva's recall of more than a million bottles of its generic version of Eli Lilly's anti-depressant, Cymbalta (duloxetine delayed-release capsules), in the US.